Luminex Corporation Begins Clinical Trials for ARIES® System and ARIES® HSV 1&2 Assay
AUSTIN, Texas, March 30, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has commenced clinical and analytical studies to evaluate the company's ARIES® System and ARIES® HSV 1&2 Assay. Luminex plans to seek both FDA clearance and CE IVD marking this year.
"We are excited to announce the start of ARIES clinical trials as planned, which represents a key milestone in our commercial launch schedule," said Homi Shamir, President and CEO of Luminex. "Because we designed ARIES to be an easy to use solution that solves many of the problems and challenges laboratories face each day, we are highly optimistic in the market potential for this innovative platform. We continue to advance along our projected launch schedule, and expect to initiate clinical trials for additional ARIES assays in the coming months. With ARIES, we are solidifying a platform which we expect will accelerate growth for years to come."
The clinical trials are being conducted at several clinical laboratories in the U.S. and Luminex expects its FDA submission for ARIES and the HSV 1&2 Assay to occur in the summer of 2015.
About ARIES
ARIES is a sample to answer system designed to deliver superior laboratory performance, increase laboratory efficiency, and fit seamlessly into today's lean laboratory environment. ARIES uses internal bar code scanning and other advanced features to minimize operator errors. Two independent magazine bays support from one to six cassettes each, allowing for STAT and Batch testing. Simultaneous IVD and Laboratory Developed Tests (LDTs) operate through a common Universal Assay Protocol. An integrated PC eliminates the need for a separate computer, stand-alone keyboard, and mouse thus maximizing valuable bench space.
To learn more or request a demo, visit: http://www.luminexcorp.com/ARIES
About Luminex Corporation
Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.
Contacts:
Luminex Investor Contact
Harriss Currie, 512.219.8020
Sr. Vice President of Finance and CFO
[email protected]
Luminex Media Contact
Christine Valle, 512.219.8020
Sr. Manager, Global Marketing
[email protected]
Photo - http://photos.prnewswire.com/prnh/20150330/195232
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
SOURCE Luminex Corporation
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article